The FDA launched a dashboard to increase transparency by showing preliminary notices sent to companies, universities, and researchers that failed to register clinical trials or report study results. Around 120 pre-notices have been sent so far to those who failed to follow federal law requiring the necessary steps. If they don’t comply, the FDA can issue a non-compliance notice and seek penalties. Some recipients of these pre-notices include Novartis, Bausch and Lomb, and Georgetown University Medical Center. This move responds to complaints about lacking compliance and aims to hold clinical trial sponsors and investigators accountable.
Source link
FDA publishes new database of wayward clinical trial sponsors
